Quick Answer
Denali Therapeutics Inc. reported Total Assets of $1.14 billion for the year ending 2025.
- Denali Therapeutics Inc. showed a decrease of -16.7% in Total Assets from 2024 to 2025.
- This data is from Denali Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $613.95 million | Q2 2018: $572.06 million | Q3 2018: $544.48 million | Q1 2019: $676.60 million | Q2 2019: $637.60 million | Q3 2019: $602.98 million | Q1 2020: $695.87 million | Q2 2020: $647.34 million | Q3 2020: $1.07 billion | Q1 2021: $1.55 billion | Q2 2021: $1.51 billion | Q3 2021: $1.45 billion | Q1 2022: $1.32 billion | Q2 2022: $1.29 billion | Q3 2022: $1.23 billion | Q1 2023: $1.41 billion | Q2 2023: $1.31 billion | Q3 2023: $1.24 billion | Q1 2024: $1.58 billion | Q2 2024: $1.50 billion | Q3 2024: $1.45 billion | Q1 2025: $1.27 billion | Q2 2025: $1.17 billion | Q3 2025: $1.06 billion.
- Over the full 9 years of available data (2017 to 2025), Denali Therapeutics Inc.'s Total Assets has grown by 135.2%.
- Historical annual values: Fiscal year 2025: $1.14 billion | Fiscal year 2024: $1.37 billion | Fiscal year 2023: $1.15 billion | Fiscal year 2022: $1.46 billion | Fiscal year 2021: $1.40 billion | Fiscal year 2020: $1.60 billion | Fiscal year 2019: $553.23 million | Fiscal year 2018: $661.98 million | Fiscal year 2017: $486.72 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: